Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 24, 2017
Pharmacy Choice - News - U.S. FDA Final Approvals (Drugs & Devices) - March 24, 2017

Pharmacy News

 U.S. FDA Final Approvals (Drugs & Devices)
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 156     Next >>     Go To Page:

3/17/17 - Astex bags milestone after Novartis cancer drug approved [Syrian Arab News Agency]
Astex Pharmaceuticals has pocketed a milestone payment from Novartis after the cancer drug the companies worked on together a decade ago secured FDA approval. The milestone was triggered when FDA signed off on the use of Kisqali as a first-line treatment for HR-positive, HER2-negative advanced breast cancer. That led to the publication of a paper o
3/17/17 - FDA Approves Merck`s Keytruda for Adult and Pediatric Patients With Classical Hodgkin Lymphoma [Sudan Tribune]
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA, the companys anti-PD-1 therapy, for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma, or who have relapsed after three or more prior lines of therapy. Under the FDAs acce
3/17/17 - FDA Approves Novartis Kisqali As Metastatic Breast Cancer Treatment [Sport360]
Reports by the American Cancer Society reveal approximately 40 percent of U.S. women battling breast tumors are affected by metastatic breast cancer. The U.S. Food and Drug Administration confirmed the approval of Kisqali, which belongs to a class of pharmaceuticals called kinase inhibitors, on March 13. According to Novartis, a month`s supply of K
3/17/17 - KISQALI (ribociclib) Approved for the Treatment of HR+/HER2- Advanced Breast Cancer, Available for Order At Biologics, Inc.
Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by Novartis to be a specialty pharmacy provider for KISQALI . Approved by the U.S. Food and Drug Administration on March 13, 2017, KISQALI is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy
3/17/17 - Toshiba Medical's New Premium Cardiovascular Ultrasound Receives FDA Clearance
The newly FDA- cleared system is the latest addition to the premium Aplio i-series ultrasound platform, helping to elevate cardiovascular ultrasound with excellent imaging clarity and definition. The Aplio i900 presents a real breakthrough in expanding the clinical utility of ultrasound, offering cardiologists a new tool for fast, safe and confi
3/17/17 - Transcatheter Device By Medtronic plc. Ordinary Shares (NYSE:MDT) Gets FDA Nod
The Melody Transcatheter Pulmonary Valve that has been developed by Medtronic plc. Ordinary Shares (NYSE:MDT) has been approved by the U.S. Food and Drug Administration. The device is implanted in patients in cases where surgical pulmonary heart valves are not working. This transcatheter pulmonary valve is the first of its kind to be approved in [
3/17/17 - ViewRay Receives FDA 510k Clearance for MRIdian Linac
ViewRay, Inc. announced that the company received 510 clearance from the U.S. Food and Drug Administration to market the MRIdian Linac system, the company's next generation linear accelerator-based MRI-guided radiation therapy system. "FDA clearance of the MRIdian Linac is a transformative milestone for ViewRay," said Chris A. Raanes, president an
3/16/17 - CeloNova Biosciences Receives FDA Approval of COBRA PzF? Stent System
By a News Reporter-Staff News Editor at Politics& Government Week CeloNova BioSciences, Inc. announced that it has received U.S. Food and Drug Administration approval of its first-in-class COBRA PzF? NanoCoated Coronary Stent System. "There continues to be an unmet clinical need for patients who may not be candidates for drug-eluting stents or
3/16/17 - Compounding: BIO Submits Comments to FDA on Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application
Release date- 15032017- The Biotechnology Innovation Organization thanks the Food and Drug Administration for the opportunity to submit comments on FDA's revised draft Guidance for Industry' Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application.'. FDA -2014- D-1525-0357: Mixing, Diluting
3/16/17 - Pfizer Announces Approval By The China Food And Drug Administration Of XELJANZ, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis
Pfizer China announced today that it has received approval from the Chinese Food and Drug Administration to market its oral Janus kinase inhibitor, XELJANZ , in China for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. Pfizer is committed t
3/16/17 - Pfizer Receives China Food And Drug Administration Approval To Market Xeljanz
NEW YORK CITY- Pfizer China, a unit of Pfizer Inc., said it has received approval from the Chinese Food and Drug Administration or CFDA to market its oral Janus kinase inhibitor, Xeljanz or tofacitinib citrate, in China for the treatment of adult patients with moderately to severely active rheumatoid arthritis or RA, who have had an inadequate resp
3/16/17 - ReaLens, LLC: The first product, the iris stabilizer/expander, is 510K approved and ready for the market.
Austin, TX, TX 78613, US. ReaLens, LLC is an ophthalmic devices manufacturer startup that has two products:. This product is FDA 510 K approved and ready for sale now.
3/15/17 - Amend Surgical Announces 510K Clearance for NanoFUSE BA
By a News Reporter-Staff News Editor at Biotech Week Amend Surgical, Inc., a medical device company focused on enhancing the regenerative capacity of bone replacement products, announced that they have received 510 clearance to market NanoFUSE BA as a bone graft extender for spine and orthopedic applications. With this most recent clearance Am
3/15/17 - BriaCell Approved by FDA for BriaVax Testing
BriaCell Therapeutics has been cleared by the FDA to begin an open-label Phase I/IIa trial of its product BriaVax in patients with advanced breast cancer. Bill Williams, President and CEO of BriaCell Therapeutics. The upcoming Phase I/IIa clinical trial is designed to determine the optimal dosing regimen for patients, further assess the vaccine
3/15/17 - Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval
Release date- 14032017- Cambridge, UK- Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its long-standing pharmaceutical collaborator, Novartis, has received US Food and Drug Administration...
3/15/17 - DJO Global Announces FDA 510(k) Clearance for Exprt Revision Hip
DJO Global, Inc., a leading global provider of medical technologies designed to get and keep people moving, today announced that its Exprt Revision Hip portfolio received market clearance by the U.S. Food and Drug Administration. The 12,000 surgeons expected to attend this year s Annual Meeting of the American Academy of Orthopaedic Surgeons
3/15/17 - Evonik's VESTAKEEP PEEK reaches milestone number of FDA clearances; Medical device FDA 510K clearances surpass 80 with VESTAKEEP PEEK
Release date- 14032017- PARSIPPANY, N.J.- Evonik Corporation's VESTAKEEP PEEK, used by medical device customers for the design and development of surgical implants, recently surpassed a milestone of more than 80 devices cleared by the U.S. Food and Drug Administration. Medical OEM's usually take one of two paths to have their devices reviewed and a
3/15/17 - FDA Clears Robot-Supported Artis Pheno Angiography System from Siemens Healthineers
Siemens Healthineers issued the following news release:. The Food and Drug Administration has cleared the ARTIS pheno, a robotic C-arm angiography system from Siemens Healthineers created for use in minimally invasive interventional procedures. With products and solutions such as the ARTIS pheno, as well as a new name that underscores the company's
3/15/17 - First Ray Receives FDA 510(k) Clearance for Expanded Stealth Staple? Product Line
First Ray, a start-up medical device company focused on advanced surgical devices for improving outcomes for orthopaedic extremity procedures, announces that it has received FDA 510 clearance for new additions to the Stealth Staple? System product family. Previously, the company received clearance for its "Standard" size implants in different l
3/15/17 - Medtronic Melody Transcatheter Pulmonary Valve First of Its Kind to Receive FDA Approval for Implantation in Failed Surgical Pulmonary Heart Valves
Release date- 14032017- DUBLIN- Medtronic plc today announced that its MelodyTranscatheter Pulmonary Valve received approval from the United States Food and Drug Administration for implantation in patients whose surgical bioprosthetic pulmonary heart valves have failed. 'As the first commercially available transcatheter heart valve, the Melody TPV.
3/15/17 - Medtronic Receives FDA Clearance for Reveal LINQ Insertable Cardiac Monitor (ICM) with TruRhythm Detection
Release date- 13032017- DUBLIN- Medtronic plc today announced U.S. Food and Drug Administration 510 clearance for its Reveal LINQ Insertable Cardiac Monitor with TruRhythm Detection, an advanced cardiac monitor offering improved accuracy to better identify abnormal heartbeats. 'For nearly twenty years, Medtronic has led innovation in cardiac monito
3/15/17 - Medtronic Receives FDA Clearance For Reveal LINQ Insertable Cardiac Monitor (ICM) With TruRhythm Detection [Tehran Times (Iran)]
Medtronic plc recently announced U.S. Food and Drug Administration 510 clearance for its Reveal LINQ Insertable Cardiac Monitor with TruRhythm Detection, an advanced cardiac monitor offering improved accuracy to better identify abnormal heartbeats. "ICMs help physicians find answers for patients at risk for cardiac arrhythmias to better manage a r
3/15/17 - NEOS THERAPEUTICS, INC. - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations
We received approval from the U.S. Food and Drug Administration, for Adzenys XR-ODT, our amphetamine XR-ODT, on January 27, 2016 and launched the commercialization of this product on May 16, 2016. On November 10, 2015, we announced that we received a Complete Response Letter from the FDA in its review of our New Drug Application, or NDA, for Cotemp
3/15/17 - Novartis Kisqali (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
Release date- 13032017- Basel- The US Food and Drug Administration has approved Kisqali in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer. 'Kisqali is emblematic of
3/15/17 - Novartis Kisqali receives FDA approval for HR+ / HER2- metastatic breast cancer [Sudan Tribune]
Swiss-based healthcare company Novartis has received approval from the US Food and Drug Administration for its Kisqali in combination with an aromatase inhibitor as the first-line treatment of advanced or metastatic breast cancer. Novartis oncology chief executive officer Bruno Strigini said: Kisqali is emblematic of the innovation that Novartis...
Articles(s): 1 - 25 of 156     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415